

Table 1. Baseline characteristics of participants.

	Chinese cohort		South Korean cohort
	Training set N=402	Validation set N=136	External validation cohort N=532
Demographics			
Age, years	42 (32-51)	43 (31-51)	54 (40-64)
Men, n (%)	301 (74.9%)	91 (66.9%)	265 (49.8%)
Metabolic factors			
BMI, kg/m ²	26.6 (24.3-28.8)	27.4 (24.3-29.1)	27.5 (25.3-30.5)
Waist circumference, cm	91.5 (86.2-97.0)	91.8 (85.6-98.0)	92.0 (86.0-100.0)
Central obesity, n (%)	273 (70.5%)	92 (70.8%)	406 (76.3%)
Type 2 diabetes, n (%)	148 (36.8%)	38 (27.9%)	202 (38.0%)
Hypertension, n (%)	172 (42.8%)	58 (42.6%)	269 (50.6%)
Metabolic syndrome, n (%)	291 (72.4%)	102 (75.0%)	390 (73.3%)
Laboratory parameters			
ALT, IU/L	53 (32-87)	51 (27-102)	46 (27-85)
AST, IU/L	34 (25-54)	33 (25-55)	39 (26-59)
γ -GT, IU/L	52 (33-81)	53 (30-93)	42 (24-72)
Albumin, g/dL	4.6 (4.4-4.8)	4.6 (4.5-4.8)	4.2 (4.0-4.4)
Glucose, mmol/L	5.3 (4.8-6.3)	5.3 (4.8-6.0)	5.8 (5.3-6.7)
Insulin, mIU/L	14.5 (9.5- 22.0)	15.8 (10.7-21.4)	14.6 (9.9-21.6)
HbA1c, %	5.7 (5.4-6.6)	5.7 (5.4-6.3)	6.0 (5.5-6.7)
HOMA-IR score	3.6 (2.3-5.5)	3.8 (2.5-5.3)	4.0 (2.6-6.2)
Platelet count, $\times 10^9/L$	247 \pm 62	249 \pm 68	238 \pm 66
TG, mmol/L	1.9 (1.4-2.8)	1.9 (1.4-2.8)	1.6 (1.2-2.2)
TC, mmol/L	5.1 \pm 1.2	5.2 \pm 1.2	4.7 \pm 1.1

HDL-C, mmol/L	1.0 (0.8-1.1)	1.0 (0.9-1.1)	1.1 (0.9-1.3)
LDL-C, mmol/L	3.0 ± 0.9	3.1 ± 0.9	2.7 ± 0.9
Genotypes, n (%)			
<i>PNPLA3</i> rs738409			
C/C	117 (29.1%)	41 (30.1%)	112 (21.1%)
C/G	187 (46.5%)	66 (48.5%)	255 (47.9%)
G/G	98 (24.4%)	29 (21.3%)	165 (31.0%)
<i>HSD17B13</i> rs72613567			
-/-	190 (47.3%)	57 (41.9%)	300 (56.4%)
-/A	176 (43.8%)	61 (44.9%)	190 (35.7%)
A/A	36 (9.0%)	18 (13.2%)	42 (7.9%)
<i>TM6SF2</i> rs58542926			
C/C	251 (83.9%)	89 (87.3%)	435 (81.8%)
C/T	45 (15.1%)	12 (11.8%)	92 (17.3%)
T/T	3 (1.0%)	1 (1.0%)	5 (0.9%)
<i>MBOAT7</i> rs641738			
C/C	224 (55.9%)	69 (50.7%)	330 (62.0%)
C/T	152 (38.1%)	56 (41.2%)	178 (33.5%)
T/T	2 (6.0%)	11 (8.1%)	24 (4.5%)
Liver histology features			
Fibrosis stage, n (%)			
F0	112 (27.9%)	36 (26.5%)	93 (17.5%)
F1	195 (48.5%)	64 (47.1%)	261 (49.1%)
F2	68 (16.9%)	30 (22.1%)	122 (22.9%)
F3	23 (5.7%)	4 (2.9%)	26 (4.9%)
F4	4 (1.0%)	2 (1.5%)	30 (5.6%)

Steatosis grade, n (%)			
S1	182 (45.3%)	69 (50.7%)	174 (32.7%)
S2	87 (21.6%)	29 (21.3%)	195 (36.7%)
S3	133 (33.1%)	38 (27.9%)	163 (30.6%)
Ballooning grade, n (%)			
B0	51 (12.7%)	22 (16.2%)	197 (37.0%)
B1	224 (55.7%)	74 (54.4%)	302 (56.8%)
B2	127 (31.6%)	40 (29.4%)	33 (6.2%)
Lobular inflammation grade, n (%)			
L0	30 (7.5%)	4 (2.9%)	86 (16.2%)
L1	298 (74.1%)	99 (72.8%)	339 (63.7%)
L2	71 (17.7%)	29 (21.3%)	104 (19.5%)
L3	3 (0.7%)	4 (2.9%)	3 (0.6%)
NAS score	4 (3-5)	4 (3-5)	4 (3-5)
Definite NASH[†]	171 (42.5%)	50 (36.8%)	178 (33.5%)

Note: ALT, alanine aminotransferase; AST, aspartate transaminase; BMI, body mass index; GGT, γ -glutamyl transpeptidase; HbA1c, hemoglobin A1c; HOMA-IR, homeostasis model assessment-insulin resistance; HDL-C, high-density lipoprotein cholesterol; *HSD17B13*, hydroxysteroid 17-beta dehydrogenase 13; LDL-C, low-density lipoprotein cholesterol; *MBOAT7*, membrane-bound O-acyltransferase domain-containing protein 7; NAFLD, non-alcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NAS, NAFLD activity score; *PNPLA3*, patatin-like phospholipase domain-containing-3; TG, triglycerides; TC, total cholesterol; *TM6SF2*, transmembrane 6 superfamily member 2.